Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Expands By 19.8%

Key Points

• Short interest rose 19.8% in April to 3,000,764 shares, equal to about 7.9% of the stock and a short‑interest ratio of 7.0 days.
• Analyst coverage is mixed but the consensus is a Moderate Buy with a target price of $10.50 (1 Strong Buy, 5 Buy, 2 Sell ratings).
• SABS opened at $3.48 with a market cap of $177.31 million; the company reported a quarterly loss of ($0.46) EPS, missing estimates and forecasting a fiscal‑year loss around ($0.72).

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totaling 3,000,764 shares, an increase of 19.8% from the March 31st total of 2,504,815 shares. Based on an average daily volume of 431,609 shares, the short-interest ratio is currently 7.0 days. Currently, 7.9% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

A number of research firms have commented on SABS. Rodman & Renshaw began coverage on shares of SAB Biotherapeutics in a report on Thursday, April 2nd. They issued a "buy" rating and a $13.00 price objective for the company. Wall Street Zen downgraded shares of SAB Biotherapeutics from a "hold" rating to a "sell" rating in a report on Saturday, March 14th. Chardan Capital increased their price objective on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a "buy" rating in a report on Wednesday, March 11th. UBS Group began coverage on shares of SAB Biotherapeutics in a report on Wednesday, January 7th. They issued a "buy" rating and a $7.00 price objective for the company. Finally, Zacks Research downgraded shares of SAB Biotherapeutics from a "hold" rating to a "strong sell" rating in a report on Thursday, March 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, SAB Biotherapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $10.50.

SAB Biotherapeutics Stock Down 1.4%

SABS stock opened at $3.48 on Thursday. The company has a market cap of $177.31 million, a price-to-earnings ratio of -1.50 and a beta of 0.60. The company has a current ratio of 9.46, a quick ratio of 9.46 and a debt-to-equity ratio of 0.02. SAB Biotherapeutics has a 12 month low of $1.53 and a 12 month high of $6.60. The firm has a 50-day moving average of $3.87 and a two-hundred day moving average of $3.74.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.30). As a group, analysts forecast that SAB Biotherapeutics will post -0.72 earnings per share for the current fiscal year.

Institutional Trading of SAB Biotherapeutics

Several hedge funds have recently made changes to their positions in SABS. ADAR1 Capital Management LLC purchased a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at approximately $30,000. Dimensional Fund Advisors LP purchased a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at approximately $32,000. State of Wyoming purchased a new stake in shares of SAB Biotherapeutics in the 4th quarter valued at approximately $34,000. Virtu Financial LLC purchased a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at approximately $40,000. Finally, State Street Corp purchased a new stake in shares of SAB Biotherapeutics in the 4th quarter valued at approximately $49,000. Hedge funds and other institutional investors own 7.82% of the company's stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.